PIK3CA Pathway and CTNNB1 Determine Poor Response of Cetuximab in Right-Sided Metastatic Colorectal Cancer

机译：Pik3CA途径和CTNNB1确定右侧转移性结肠直肠癌中西妥昔单抗的良差

获取原文

页面导航

摘要
著录项
相似文献
相关主题

摘要

Background: Clinical observation showed right-sided colorectal cancer (CRC) exhibited worse outcome in patients treated with cetuximab. Large molecular studies also highlight the facts that distinguish pattern of molecular profile exist in left and right side of CRC. However, the link of therapy outcome and molecular profile in different location of primary tumors is unclear.

机译：背景：临床观察显示右侧结直肠癌（CRC）表现出患者治疗的患者的较差的结果。大分子研究还突出了分子曲线模式存在于CRC的左侧和右侧的事实。然而，原发性肿瘤的不同位置的治疗结果和分子曲线的链接尚不清楚。

著录项

来源
《International Molecular Medicine Tri-Conference.》|2019年|1 DVD-ROM ;|共1页
会议地点
作者
Pi-Yueh Chang;
展开▼
作者单位

展开▼
会议组织
原文格式 PDF
正文语种
中图分类 R393;
关键词

相似文献

外文文献
中文文献
专利

1. 肝血管生成:在非转移性结肠直肠癌中肿瘤宿主的相互作用 [J] . Khaled Abdel-Hakim, Nagwa El-Nefiawy 中德临床肿瘤学杂志（英文版） . 2011,第010期
2. PIK3CA Pathway Mutations Predictive of Poor Response Following Standard Radiochemotherapy +/- Cetuximab in Cervical Cancer Patients [J] . de la Rochefordiere Anne, Kamal Maud, Floquet Anne, Clinical cancer research: an official journal of the American Association for Cancer Research . 2015,第11期

机译：PIK3CA途径突变可预测宫颈癌患者标准放化疗+/-西妥昔单抗后反应不良
3. High early growth response 1 (EGR1) expression correlates with resistance to anti-EGFR treatment in vitro and with poorer outcome in metastatic colorectal cancer patients treated with cetuximab [J] . S. S. Kumar, Y. Tomita, J. Wrin, Clinical & translational oncology : . 2017,第6期

机译：高早期生长响应1（EGR1）表达与体外抗EGFR治疗的抗性相关，并在转移性结肠直肠癌患者中较差的转移性结肠直肠癌患者治疗
4. Efficacy of CapeOX plus Cetuximab Treatment as a First-Line Therapy for Patients with Extended RAS/BRAF/PIK3CA Wild-Type Advanced or Metastatic Colorectal Cancer [J] . Journal of Cancer . 2018,第22期

机译：Capeox加入西司昔单抗治疗作为延长RAS / BRAF / PIK3CA野生型先进或转移结直肠癌患者的一线治疗的疗效
5. PIK3CA Pathway and CTNNB1 Determine Poor Response of Cetuximab in Right-Sided Metastatic Colorectal Cancer [C] . Pi-Yueh Chang International Molecular Medicine Tri-Conference. . 2019

机译：Pik3CA途径和CTNNB1确定右侧转移性结肠直肠癌中西妥昔单抗的良差
6. Combination of Cetuximab and Oncolytic Virus Canerpaturev Synergistically Inhibits Human Colorectal Cancer Growth [D] . Wu Zhiwen, 吴智闻 2019

机译：西妥昔单抗和溶瘤病毒Canerpaturev的组合协同抑制人类大肠癌的生长。
7. Efficacy of CapeOX plus Cetuximab Treatment as a First-Line Therapy for Patients with Extended RAS/BRAF/PIK3CA Wild-Type Advanced or Metastatic Colorectal Cancer [O] . Shigeyoshi Iwamoto, Hiromichi Maeda, Shoichi Hazama, 2018

机译：CapeOX联合西妥昔单抗治疗扩展型RAS / BRAF / PIK3CA野生型晚期或转移性结直肠癌患者的一线治疗的疗效
8. Efficacy of CapeOX plus Cetuximab Treatment as a First-Line Therapy for Patients with Extended RAS/BRAF/PIK3CA Wild-Type Advanced or Metastatic Colorectal Cancer [O] . Shigeyoshi Iwamoto, Hiromichi Maeda, Shoichi Hazama, 2018

机译：Capeox加入西司昔单抗治疗作为延长RAS / BRAF / PIK3CA野生型先进或转移结直肠癌患者的一线治疗的疗效

PIK3CA Pathway and CTNNB1 Determine Poor Response of Cetuximab in Right-Sided Metastatic Colorectal Cancer

摘要

著录项

相似文献

相关主题

期刊订阅